On March 20, 2026, Novo Nordisk's patent on semaglutide expired in India, triggering one of the most significant transformations in the country's pharmaceutical history. Within weeks, more than 40 Indian…
🔬 WHO-GMP Certification for Indian Generics: What the New Schedule M Rules Mean for You India supplies approximately 20% of the world's generic medicines by volume, making it the largest…
The Central Drugs Standard Control Organization (CDSCO), India's national drug regulatory authority, has undertaken the most significant regulatory modernization in its history during the first half of 2026. From introducing…
The United States imposed a sweeping 100% tariff on patented pharmaceutical imports on April 2, 2026, under Section 232 of the Trade Expansion Act. However, generic medicines — which make…